All News

Arena Pharmaceuticals’ and marketing partner Eisai’s Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September.

While buzz on Twitter will never outweigh critical data in a peer-reviewed publication, social media is becoming an important part of our industry’s dialogue. The oncology market is no exception, as insight gleaned from recent Twitter traffic and trends reveals.

Sophie Biernaux, VP & vaccine development leader, malaria and Joe Cohen, advisor malaria vaccine program, at GSK Vaccines at PhRMA?s Research and Hope Awards ceremonyon their innovative approach to vaccine development

A significant, though as yet not fully understood player in the launch of Obamacare is the pharmacy benefit manager (PBM) industry.

Advances in health information technology and new federal financial incentives are fueling rapid growth in the use of electronic medical record (EMR) systems

Like the Super Bowl, pharma companies are winning major congresses by using competitive conference techniques to generate brand buzz and corporate recognition.

Everything dies eventually. Print… Dead. Television… Dead… Even God… Dead. Well hold on to your hats, someone has said it, digital marketing is no more.

A new study shows the importance of intellectual property in stimulating jobs and productivity in the EU.

Compliance rules under the US Physician Payments Sunshine Act have been criticized for the excruciating level of detail demanded from individual company submissions.

The data-transparency bandwagon is rolling rapidly across Europe, energetically propelled by regulators, health campaigners, and generic manufacturers.

In health care, it is the lowly consumer who is now calling the shots, driving product and process innovation in areas ranging from electronic medical records [EMR] to retail health clinics.

Writing last week on this blog, Beth Bengtson, principal at healthcare marketing and communications company Hale Advisors, highlighted the problem posed for public health by Wikipedia.

Morten Hjelmsoe offers a quick review of the development of our communication technologies- and looks forward to what’s coming next.

George Mina, Pfizer's Director/TL-Data Strategy & Reconciliation-Transparency Medical Division - External Medical Communications, on the challenges of implementing the Physician Payment Sunshine Act for pharmaceutical companies

Medical articles on Wikipedia receive about 150 million page views per month, and nearly 50% of practicing physicians use Wikipedia as an information source for providing medical care. And while Wikipedia itself has disclaimers that information included on its site may be inaccurate,

A major Inquiry into access to new medicines across Scotland by the Scottish Health and Sport Committee has come to an end. The Scottish Government has responded, and announced changes to how Scotland makes decisions on what new medicines to use across the NHS in Scotland.

An increasing number of small biotech companies are being hatched to focus on a single disease or condition. The strategy goes against the diversified portfolio approach most big pharma companies have embraced, and instead puts all the eggs in one basket.

The UK Prime Minister David Cameron has announced that the Cancer Drugs Fund (CDF) in England - which covers the cost of cancer treatments either when the National Institute for Health and Care Excellence (NICE) has said ‘no’, or hasn’t yet come to a view - will be extended to April 2016.

Another temporary casualty of the US government shutdown is the negotiation process surrounding the US and Europe’s free trade agreement.

Officials from the Food and Drug Administration and the National Institutes of Health were scheduled to explain developments in clinical trial registration and transparency at the Drug Information Association’s conference on Clinical Trial Disclosure in Bethesda, Md. this week.

As the health insurance marketplaces begin enrollment this week and go live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and the millions of consumers purchasing health insurance for the first time through an exchange.

The Multiple Myeloma Research Foundation (MMRF) has launched a new initiative to increase the pace of innovation in myeloma research through faster cures and more efficient, timely trials for patients

PE June 2013 BPA

Predictive analysis has been used to great effect in the finance, tech, retail, and telecoms industries. Can it also improve decision-making and health outcomes in life sciences?

Planning to submit to the FDA today? Think again. The agency put a forced pause on key services and functions – and furloughed 6,620 FDA employees – as a result of last night’s government shutdown.

For more than three years, the US pharmaceutical industry has known that today would arrive. So this is it. The first day that eligible U.S. citizens can sign up for Obamacare - and enjoy the prospect of prescription drug insurance, effective January 1st, 2014.

Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small biotech firm that focuses on ultra-rare disease.

Doing deals with storytellers could be as important for pharma as collaborating with research scientists, writes Peter Houston.

George Mina, Pfizer's Director/TL-Data Strategy & Reconciliation-Transparency Medical Division - External Medical Communications, on the challenges of implementing the Physician Payment Sunshine Act for pharmaceutical companies

Dr. Shantanu Agrawal, director of data sharing & partnership group and the medical director for the center for program integrity at CMS on the Physician Payment Sunshine Act